Retatrutide Brand Name, Manufacturer and FDA Status (2026)

Direct answer: Retatrutide does not have a brand name, a trade name, or any other commercial name. Retatrutide is itself the generic name -- the nonproprietary INN and USAN adopted for the molecule in 2022. Eli Lilly and Company is the sole manufacturer, and internally the drug carries the research compound code LY3437943. A trademarked brand name gets assigned when Lilly files for approval, and Lilly has now stated it plans to submit retatrutide to the FDA in Q1 2027. That filing is the event to watch.

Quick Stats

Key Takeaways

• Eli Lilly is the sole manufacturer of retatrutide -- the same company that made Mounjaro and Zepbound
• The drug's official research name is LY3437943 -- no brand name has been announced yet, and "retatrutide" is the generic name, not a brand
• Retatrutide is in Phase 3 trials under the TRIUMPH clinical program, with five positive Phase 3 readouts between December 2025 and July 2026
• The best Phase 3 result to date is 30.3% average body weight loss at 104 weeks in TRIUMPH-1's extension, and 28.3% at 80 weeks -- the highest figures reported in a late-stage obesity trial
• Lilly said in July 2026 that its clinical data package is complete and it will file a Biologics License Application (BLA), not an NDA, in Q1 2027
• FDA approval therefore cannot realistically land before late 2027, and 2028 is possible
• Product names circulating online, including Salkalli, are not Lilly brands and are not FDA approvals

Knowing who makes a drug might sound like a trivial detail. But when you are tracking something that could genuinely change how obesity is treated, the manufacturer's history shapes everything -- from how fast approval moves to whether your insurance will actually cover it. Lilly is not a newcomer here. They have already navigated this exact road with tirzepatide, and as of April 2026 they have done it a third time with an oral GLP-1.

Here is everything you need to know about Eli Lilly's role in retatrutide's development, what the drug is called, and what happens next.

What Is Retatrutide Brand Name? The Direct Answer

The question "what is retatrutide brand name" comes up often, and the answer is straightforward: there is no brand name yet.

There is also no trade name, which is the same thing under a different label. "Brand name," "trade name" and "proprietary name" all describe the trademarked commercial name a manufacturer attaches to a drug at approval. Retatrutide has none of them.

What retatrutide does have is a generic name, and the generic name is simply retatrutide. That word is the International Nonproprietary Name (INN) and the United States Adopted Name (USAN), both adopted in 2022. The -tide ending is the USAN stem that marks the molecule as a peptide. Generic names are assigned early in development by naming councils, years before any brand name exists, which is why a drug can have a generic name and nothing else for a decade.

When people search for the retatrutide brand, they typically find the drug's research designation -- LY3437943 -- which is Eli Lilly's internal compound code, not a commercial name. Brand names are only assigned during the regulatory filing process, which Lilly has not yet initiated for retatrutide.

For comparison: tirzepatide's research designation was LY3298176 for years before Lilly gave it the commercial names Mounjaro (for type 2 diabetes) and Zepbound (for obesity). Retatrutide will follow the same path. The retatrutide brand name will emerge when Lilly prepares its regulatory submission -- not before.

Until then, the correct terms to use are: retatrutide, LY3437943, or Eli Lilly retatrutide.

Retatrutide Brand: What to Expect When Lilly Names It

The retatrutide brand will be assigned by Eli Lilly during the FDA filing process. Lilly said on 23 July 2026 that it is completing the Chemistry, Manufacturing, and Controls data package required for a Biologics License Application and "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval." Proposed proprietary names are reviewed by FDA as part of that submission, so the earliest a brand name realistically becomes public is 2027.

Note the filing type. Coverage that says Lilly will file an NDA for retatrutide is out of date: Lilly has specified a BLA, the pathway used for biologic products, and confirmed it again in its Q2 2026 results on 5 August 2026.

Predicted Retatrutide Brand Naming Pattern

Based on how Lilly named tirzepatide (Mounjaro for T2D, Zepbound for obesity), how Novo named semaglutide (Ozempic for T2D, Wegovy for obesity, Rybelsus for the pill), and how Lilly named orforglipron (Foundayo, approved 1 April 2026), the retatrutide brand strategy is likely to follow the same template:

One caveat on the two-brand assumption. Orforglipron, Lilly's most recent launch, currently carries one brand: Foundayo, approved for chronic weight management only. Lilly submitted orforglipron for type 2 diabetes separately and has not said whether that indication gets a second name. So a single-brand outcome for retatrutide is possible too.

The retatrutide brand names themselves have not been published or trademarked publicly. Watch the USPTO trademark database through 2026 and into early 2027 for the first signals -- Lilly typically files trademarks 6--12 months before a brand launch.

Why the Retatrutide Brand Name Matters

The brand name affects:

• Insurance coverage codes — brand-specific PA criteria
• Patient assistance program eligibility — savings cards apply per brand
• Cash-pay direct programs — LillyDirect lists by brand
• Off-label vs on-label prescribing — obesity brand cannot be prescribed for diabetes and vice versa, even though it's the same molecule
• Search and marketing visibility — brand searches dominate volume once approved

Until the retatrutide brand is announced, "retatrutide" remains the only correct term to use in prescriptions, insurance discussions, and patient communications.

Retatrutide Brand Names You Will Find Online, and Why None of Them Are Real

Search hard enough for a retatrutide brand name and you will eventually hit product names that look official. They are not, and it is worth knowing exactly what you are looking at.

Salkalli is the name that turns up most often. It appears in DailyMed, the U.S. National Library of Medicine's drug label database, attached to eight retatrutide product listings: pens at 10 mg, 30 mg and 40 mg, and lyophilized powder vials at 2.5 mg, 5 mg, 7.5 mg and 10 mg. All of them, plus two unbranded "Retatrutide Pen" and "Retatrutide Lyophilized Powder" listings, were submitted by the same labeler, Guangzhou Yixin Cross-border E-commerce Co., Ltd., and published on 17 November 2025.

Finding a drug name in a government database feels like validation. Here it is the opposite. Every one of those ten listings carries the marketing category "Export only" (FDA code C73590). That category means a labeler self-registered a product it states is manufactured for export rather than U.S. sale. A structured product label is a filing, not a review: FDA does not evaluate safety, efficacy or quality before a label appears in DailyMed, and it does not grant brand names that way. The Salkalli labels nevertheless make treatment claims -- "to improve blood glucose control in adults with type 2 diabetes" and "for long-term weight management and reduction of visceral fat" -- that no regulator anywhere has approved for retatrutide.

Separately, at least seven manufacturers have registered retatrutide with FDA as a bulk ingredient, a category for active pharmaceutical ingredient suppliers rather than finished medicines. Those registrations are also filings, not approvals.

The search that settles the question is Drugs@FDA, the database of drugs FDA has actually approved. It returns no results at all for retatrutide.

Lilly's Position on Unapproved Retatrutide

Lilly has been unambiguous, and increasingly aggressive, about products sold under these names. On 12 August 2026 the company announced six new lawsuits against U.S. entities selling black-market retatrutide, including compounding pharmacies, medical spas and online sellers, and said it had referred more than 200 individuals and entities to FDA, the Department of Justice, state attorneys general and licensing boards. It reported more than 14,000 websites, ads, social posts and product listings marketing retatrutide across more than 100 countries.

In that release Lilly stated plainly: "No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world. It cannot be sold to consumers." Its chief medical officer added: "What is being sold on the black market is not a medicine -- it is entirely unverified, unapproved and not worth the risk." Lilly also noted FDA's position that retatrutide cannot lawfully be compounded and that so-called "research-use only" products "are of unknown quality and may be harmful."

The practical takeaway for anyone reading a vendor page: a product name on a vial tells you nothing about who made the contents, at what purity, or whether the label dose is real. There is no authorised retatrutide brand to compare it against, because there is no authorised retatrutide. Our guide to where to buy retatrutide looks at that market from the buyer's side.

Who Makes Retatrutide? Meet Eli Lilly

Eli Lilly and Company is an Indianapolis-based pharmaceutical company with over 145 years in the business. They are behind Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (also tirzepatide) for obesity.

Lilly did not stumble into GLP-1 drugs. They built their GLP-1 franchise deliberately, starting with dulaglutide (Trulicity) in 2014, then advancing to tirzepatide's dual GIP/GLP-1 mechanism. Retatrutide is the next evolution -- a triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors simultaneously.

That triple mechanism is what separates it from anything currently on the market. Semaglutide (Wegovy/Ozempic) acts on one receptor. Tirzepatide acts on two. Retatrutide acts on three, and the Phase 3 data suggests that extra lever produces meaningfully greater weight loss. For a deeper look at the science, see our guide on what is retatrutide.

Lilly's Track Record: Why It Matters

Lilly has already done the GLP-1 approval process three times -- Mounjaro was approved for type 2 diabetes in 2022, Zepbound for obesity in November 2023, and Foundayo (orforglipron), the oral GLP-1, on 1 April 2026. They understand the FDA's expectations, they have established manufacturing infrastructure, and they have real-world data on what it takes to bring a GLP-1 class drug to market at scale.

That matters for three specific reasons:

Speed. Lilly already has relationships with FDA reviewers who know their safety and efficacy data submission format. That does not mean shortcuts, but it does mean fewer back-and-forth delays.

Manufacturing. One of the biggest bottlenecks after Mounjaro approval was supply. Lilly was caught somewhat flat-footed and had to ramp manufacturing capacity quickly. They have since invested billions in new facilities specifically to avoid a repeat with the next generation of drugs, including a further $4.5 billion committed across Indiana sites in 2026. Manufacturing is also the current gating item for retatrutide: Lilly's stated reason for a Q1 2027 filing is that it is still completing the CMC data package, not that it is waiting on clinical results.

Insurance access. The pattern with tirzepatide was frustrating -- initially limited coverage, slow formulary decisions, high out-of-pocket cost. Lilly launched patient savings programs and pushed back on insurance denials with clinical data. Expect a similar playbook with retatrutide, but with more leverage now that Lilly's obesity drugs are established in the market.

The TRIUMPH Clinical Program Explained

Lilly named their Phase 3 retatrutide program TRIUMPH -- a suite of large clinical trials studying retatrutide across different patient populations. The initial registrational program began in 2023 and enrolled more than 5,800 participants across four global trials. A parallel diabetes program runs under the TRANSCEND-T2D name.

Here is the full picture as of August 2026:

The breadth of these trials is deliberate. Lilly wants approval across multiple indications -- not just obesity, but diabetes, cardiovascular disease, sleep apnea, knee osteoarthritis and chronic low back pain. That expands the potential patient base significantly and strengthens the case for insurance coverage. Lilly has said the initial submission will cover obesity, knee osteoarthritis pain, and obstructive sleep apnea.

What the Phase 3 Data Actually Shows

The numbers coming out of the TRIUMPH trials are remarkable, even by the high standards that Mounjaro already set. Five Phase 3 readouts have now landed, all positive.

TRIUMPH-1 (reported 21 May 2026) is the headline obesity trial. At 80 weeks, from an average baseline of 248.5 lbs:

In a pre-specified extension of 532 participants with a baseline BMI of 35 or above, those continuing on 12 mg to 104 weeks lost an average of 85.0 lbs, or 30.3% of body weight. That is the largest average weight loss reported in an obesity trial to date.

TRIUMPH-4 (reported 11 Dec 2025), in adults with obesity and knee osteoarthritis, produced up to 28.7% weight loss (71.2 lbs) at 68 weeks against 2.1% on placebo, a difference of 26.6 percentage points, alongside a 4.5-point reduction in WOMAC pain score.

TRIUMPH-2 and TRIUMPH-3 (both reported 23 July 2026) covered the harder populations. In TRIUMPH-2, adults with type 2 diabetes lost 12.7%, 19.1% and 20.8% at 4 mg, 9 mg and 12 mg over 80 weeks, with A1C reductions of up to 1.6%. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 22.6% (55.8 lbs). Weight loss is consistently lower in people with type 2 diabetes, which matches the pattern seen with every other incretin drug.

TRANSCEND-T2D-1, presented at the ADA Scientific Sessions in June 2026 and published in The Lancet, showed A1C reductions of up to 2.0% at 40 weeks, with up to 90% of participants reaching an A1C below 7.0%.

Phase 2 data published in the New England Journal of Medicine (2023) showed 24.2% weight loss at 48 weeks -- already the highest ever reported for a single-agent obesity medication at the time.

Safety. The adverse event profile is broadly what you would expect from an incretin: nausea, diarrhea, constipation and vomiting, all dose-dependent. Two signals deserve specific attention. Dysesthesia, an abnormal sense of touch, occurred in 5.1%, 12.3% and 12.5% of TRIUMPH-1 participants at 4 mg, 9 mg and 12 mg versus 0.9% on placebo. Urinary tract infections ran slightly above placebo as well. Lilly reports these events were generally mild to moderate, that the majority resolved during treatment, and that most participants continued therapy. Discontinuation due to adverse events reached 11.3% at the 12 mg dose in TRIUMPH-1 and 13.5% at 12 mg in TRIUMPH-3, against roughly 5% on placebo. That is a real tolerability cost at the top dose, and it is the sort of detail FDA will scrutinise.

How Does Retatrutide Compare to Mounjaro and Zepbound?

All three drugs came out of Lilly's labs, but they are meaningfully different molecules. Think of them as an evolution, not competitors.

Mounjaro / Zepbound (tirzepatide): Dual agonist targeting GIP and GLP-1. Approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Produces up to approximately 22.5% weight loss.

Retatrutide (LY3437943): Triple agonist targeting GIP, GLP-1, and glucagon. Still investigational. Phase 3 data shows 28.3% weight loss at 80 weeks and 30.3% at 104 weeks in the extension -- a clear step up.

The glucagon receptor adds direct increases in energy expenditure and fat burning. The GLP-1 and GIP components suppress appetite and slow gastric emptying. Together, they address weight from multiple biological angles at once.

A direct head-to-head is already running. TRIUMPH-5 randomises 800 adults with obesity to retatrutide or tirzepatide, with primary completion due in November 2026. That trial, not cross-study comparison, will settle the question.

For a detailed head-to-head breakdown, see: retatrutide vs semaglutide.

Current FDA Status: Where Things Stand in 2026

As of August 2026, retatrutide remains investigational -- meaning it is not FDA approved and not legally available as a prescription medication in the United States. A search of Drugs@FDA returns no approved retatrutide application of any kind.

What changed in 2026 is that the clinical uncertainty largely resolved. After TRIUMPH-2 and TRIUMPH-3 read out in July, Lilly stated it now has "the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea." The remaining work is manufacturing documentation.

This is later than most media coverage suggests. Articles written in 2024 and 2025 projected 2026 approval, and many still describe the filing as an NDA. Both are wrong. Lilly's own guidance, repeated in its Q2 2026 results on 5 August 2026, is a BLA in the first quarter of 2027.

For a more detailed approval timeline, see our article on when will retatrutide be available.

Can You Get Retatrutide Before Approval? Lilly's Expanded Access Program

There is now one lawful route to retatrutide outside a clinical trial, and it is narrow.

In August 2026 Lilly opened a pre-approval expanded access program for retatrutide, registered on ClinicalTrials.gov as NCT07629401 and listed as available. It provides single-patient access for adults with severe obesity who have run out of options. The stated criteria are strict:

• Age 18 or older
• BMI of 35 kg/m² or higher despite adherence to and tolerance of the highest available dose of an approved weight management therapy
• Two or more serious or life-threatening obesity-related complications currently being treated
• Unable to join an ongoing retatrutide trial, either because of eligibility criteria or because no site is reasonably accessible
• All standard options, including bariatric surgery, already discussed through shared decision-making

Requests go through a treating physician, not the patient. Lilly directs physician enquiries to 1-800-LillyRx (1-800-545-5979) or ClinicalTrials@lilly.com. Enrolment in a TRIUMPH or TRANSCEND trial remains the more common route; you can search active sites on ClinicalTrials.gov by NCT number using the table above.

Expanded access is not a workaround for people who simply want the drug early. It exists for patients whose situation is genuinely refractory, and the two-complication requirement is doing most of the filtering.

What Approval Could Mean for Access and Cost

If you have watched the tirzepatide rollout, you already have a preview of what retatrutide's launch might look like -- and it is a mixed picture.

Pricing: Lilly launched Zepbound at around $1,059 per month list price without insurance, and has since cut its cash-pay prices, which the company cited in its Q2 2026 results as a factor in lower realized prices. Based on retatrutide's positioning as a premium next-generation product, expect launch pricing at or above the current tier. Out-of-pocket cost without insurance will be significant.

Insurance coverage: GLP-1 drugs for obesity have had a difficult relationship with insurers. Medicare still does not cover obesity-only GLP-1 prescriptions (it requires a covered comorbidity). Commercial insurance coverage is inconsistent. Lilly's Mounjaro/Zepbound experience gives them data to push back on denials.

Savings programs: Lilly has run savings card programs for Zepbound that bring costs under $200 per month for eligible commercially-insured patients. A similar program for retatrutide is likely.

Step therapy: Insurers will likely require patients to try cheaper options first -- meaning semaglutide, tirzepatide or now oral orforglipron -- before approving retatrutide.

The bottom line: even with approval, access will not be immediate or equal. The same dynamics that made Zepbound difficult to obtain for many patients will apply here, at least initially.

Where Retatrutide Fits in Lilly's Pipeline

Retatrutide is not a standalone bet -- it is a key piece of Lilly's long-term strategy in the cardiometabolic drug market.

Lilly's oral GLP-1 orforglipron is no longer a pipeline item: FDA approved it on 1 April 2026 under the brand name Foundayo, for chronic weight management in adults with obesity or with overweight plus a weight-related condition, and Lilly has since submitted it for type 2 diabetes. By Q2 2026 Foundayo had joined Lilly's list of key products. That approval is the single most useful precedent available for how retatrutide's brand name will arrive: a nonproprietary name for years, then a trademarked name that surfaces with the filing.

Lilly is simultaneously expanding indications for tirzepatide and running a 10,000-participant cardiovascular and kidney outcomes trial for retatrutide that will not complete until 2029. The obesity drug market is projected to reach $100 billion annually by 2030, and Lilly intends to hold a major share of it.

Retatrutide's role in that picture: the premium injectable option for patients who need maximum efficacy -- those with severe obesity, multiple comorbidities, or who have not responded adequately to tirzepatide. It is not meant to replace Zepbound; it is meant to sit above it in the portfolio.

Frequently Asked Questions

Who manufactures retatrutide?

Eli Lilly and Company, headquartered in Indianapolis, Indiana, is the sole manufacturer and developer of retatrutide. The drug was developed entirely in-house as part of Lilly's GLP-1 research program, which also produced Mounjaro and Zepbound.

What is retatrutide brand name?

Retatrutide does not have an official brand name. Its research designation is LY3437943. A trademarked brand name will be announced when Lilly submits retatrutide to the FDA, which the company has said it plans to do in Q1 2027.

What is retatrutide's trade name?

It does not have one. "Trade name" is another term for brand name or proprietary name, and retatrutide has no trademarked name in any market. The only names in use are the generic name retatrutide and Lilly's internal research code LY3437943. Any trade name you see attached to a retatrutide product for sale was not assigned by Lilly and does not reflect any regulatory approval.

What is the generic name for retatrutide?

Retatrutide is the generic name. It is the International Nonproprietary Name (INN) and the United States Adopted Name (USAN), both adopted in 2022, and the -tide suffix is the USAN stem used for peptides. This is the reverse of the usual situation: most people meet a drug by its brand name and later learn the generic. With retatrutide the generic name exists and the brand name does not, because generic names are assigned during development and brand names only at filing.

What is Salkalli, and is it the retatrutide brand name?

No. Salkalli is a name appearing on eight retatrutide product listings in FDA's DailyMed database, submitted in November 2025 by Guangzhou Yixin Cross-border E-commerce Co., Ltd. All of them are filed under the marketing category "Export only," which is a self-submitted product listing rather than an FDA review or approval. Lilly has no connection to it, and Drugs@FDA shows no approved retatrutide product.

Is retatrutide a peptide, and do peptide vendors sell a branded version?

Retatrutide is a peptide, a synthetic chain of amino acids given by once-weekly subcutaneous injection, which is why it shows up on research-chemical vendor sites. None of those vendors sell a branded retatrutide, because no brand exists. Lilly stated in August 2026 that "no medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world" and has filed lawsuits against U.S. sellers, including ones marketing product as "research use only." FDA's position is that unapproved retatrutide cannot lawfully be sold to consumers or compounded.

When will the retatrutide brand name be announced?

Most likely in 2027. Proposed proprietary names are submitted to and reviewed by FDA as part of a marketing application, and Lilly has stated it plans to file its BLA in Q1 2027. Trademark filings usually appear 6--12 months ahead of a launch, so USPTO records are the earliest public signal.

Is retatrutide FDA approved?

No. Retatrutide is still an investigational drug as of August 2026, and Drugs@FDA lists no approved application for it. All five completed Phase 3 trials have been positive, and Lilly says its clinical data package is complete, but the Biologics License Application is not planned until Q1 2027. Approval before late 2027 is not realistic.

How is retatrutide different from semaglutide and tirzepatide?

Semaglutide (Ozempic/Wegovy) is a single GLP-1 receptor agonist. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors. Retatrutide hits all three -- GLP-1, GIP, and glucagon receptors. That triple action appears to produce greater weight loss than either predecessor based on current clinical data, and TRIUMPH-5 is testing it head-to-head against tirzepatide with results due after November 2026.

What is the TRIUMPH program?

TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. The initial registrational program comprised four global trials, began in 2023 and enrolled more than 5,800 participants; the program has since expanded to TRIUMPH-9, with a parallel diabetes program running under the TRANSCEND-T2D name. TRIUMPH-1 through TRIUMPH-4 and TRANSCEND-T2D-1 have all reported positive results, between December 2025 and July 2026.

How much weight loss does retatrutide cause?

The best Phase 3 result is 30.3% of body weight (85.0 lbs) at 104 weeks in the TRIUMPH-1 extension, among participants with a baseline BMI of 35 or above who stayed on the highest tolerated dose. At the standard 80-week endpoint, TRIUMPH-1 showed 28.3% (70.3 lbs) at 12 mg. TRIUMPH-4 showed 28.7% (71.2 lbs) at 68 weeks. Results are lower in people with type 2 diabetes: 20.8% in TRIUMPH-2.

Will retatrutide be covered by insurance?

There is no way to know for certain until it is approved and Lilly negotiates formulary placement. Based on the tirzepatide experience, initial coverage will be inconsistent -- especially for obesity without a listed comorbidity. Commercial insurers will likely require prior authorization and possibly step therapy. Medicare coverage for obesity-only indications remains a legislative question.

What is the official retatrutide brand name?

There is no official retatrutide brand name. Retatrutide's research designation is LY3437943, and "retatrutide" itself is the generic name. Eli Lilly will announce the commercial brand name when it files its Biologics License Application with the FDA, planned for Q1 2027. For comparison: tirzepatide's brand names are Mounjaro (diabetes) and Zepbound (obesity); semaglutide's are Ozempic (diabetes) and Wegovy (obesity); orforglipron's is Foundayo. When retatrutide reaches market, expect a similar branded structure. If you searched "what is retatrutide brand name", the short answer is: it doesn't have one yet — only the research code LY3437943 and the generic name retatrutide.

Where Things Stand Right Now

Retatrutide is Eli Lilly's drug, built on the same research foundation that produced three already-successful obesity and diabetes medications. The retatrutide brand name does not exist yet, but the compound does -- and so does a completed Phase 3 evidence package supporting it.

Lilly has demonstrated they can take a complex hormonal molecule from Phase 2 excitement to real-world prescription drug, repeatedly. The TRIUMPH program has delivered. The question is no longer whether retatrutide works -- five positive Phase 3 readouts have answered that -- but how quickly Lilly can finish its manufacturing submission, how FDA weighs the dysesthesia and discontinuation data, and whether the approval lands with a profile insurers and patients can work with.

If you are thinking about future access, the date to hold onto is Q1 2027. That is when Lilly files, when a brand name becomes public, and when the approval clock actually starts.

Want to explore more about this drug? Check out these related guides:

• What is retatrutide?
• When will retatrutide be available?
• Retatrutide vs semaglutide: how do they compare?

Currently researching peptides? Synthro Lab offers rigorously tested research compounds with transparent lab verification.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide (LY3437943) is an investigational drug that has not received FDA approval. Do not attempt to obtain or use retatrutide outside of an approved clinical trial or Lilly's expanded access program. Always consult a licensed healthcare provider before making any decisions about medications or weight management treatments. Eli Lilly has not reviewed or endorsed this content.

References

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023. PubMed 37366315
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022. PubMed 35658024
3. Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026. Lilly press release
4. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). May 21, 2026. Lilly press release
5. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). December 11, 2025. Lilly press release
6. Eli Lilly and Company. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress. August 5, 2026. Lilly press release
7. Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. August 12, 2026. Lilly press release
8. ClinicalTrials.gov. Pre-approval Expanded Access of Retatrutide (LY3437943). NCT07629401. ClinicalTrials.gov record
9. ClinicalTrials.gov. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-1). NCT05929066. ClinicalTrials.gov record
10. DailyMed, U.S. National Library of Medicine. SALKALLI (retatrutide pen 30mg) injection, solution. Guangzhou Yixin Cross-border E-commerce Co., Ltd. Published November 17, 2025. DailyMed label
11. U.S. Food and Drug Administration. Drugs@FDA: FOUNDAYO (orforglipron), NDA 220934, Eli Lilly and Company, approved April 1, 2026. Drugs@FDA